These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32652830)

  • 1. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X
    Saleh T; Carpenter VJ; Tyutyunyk-Massey L; Murray G; Leverson JD; Souers AJ; Alotaibi MR; Faber AC; Reed J; Harada H; Gewirtz DA
    Mol Oncol; 2020 Oct; 14(10):2504-2519. PubMed ID: 32652830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
    Ahmadinejad F; Bos T; Hu B; Britt E; Koblinski J; Souers AJ; Leverson JD; Faber AC; Gewirtz DA; Harada H
    Mol Pharmacol; 2022 Mar; 101(3):168-180. PubMed ID: 34907000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
    Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
    Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
    Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
    Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer.
    Carpenter V; Saleh T; Chakraborty E; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
    Biochem Pharmacol; 2024 Aug; 226():116385. PubMed ID: 38909784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
    Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
    Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
    González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
    Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Senolysis of gemcitabine-induced senescent human pancreatic cancer cells.
    Hoque MM; Iida Y; Kotani H; Harada M
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2075. PubMed ID: 38662379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice.
    Pan J; Li D; Xu Y; Zhang J; Wang Y; Chen M; Lin S; Huang L; Chung EJ; Citrin DE; Wang Y; Hauer-Jensen M; Zhou D; Meng A
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):353-361. PubMed ID: 28479002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.
    Ritter V; Krautter F; Klein D; Jendrossek V; Rudner J
    Cell Death Dis; 2021 Jul; 12(7):694. PubMed ID: 34257274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents that target senescent cells: the flavone, fisetin, and the BCL-X
    Zhu Y; Doornebal EJ; Pirtskhalava T; Giorgadze N; Wentworth M; Fuhrmann-Stroissnigg H; Niedernhofer LJ; Robbins PD; Tchkonia T; Kirkland JL
    Aging (Albany NY); 2017 Mar; 9(3):955-963. PubMed ID: 28273655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
    He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
    Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
    Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
    Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J; Chen Y; Wan J; Liu X; Yu C; Li W
    Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.